Desk›Healthcare› Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd
BSE 506879 · NSE GUJTHEM · ISIN INE942C01045 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹412.90
-1.71%
BSE close, 28 August 2026
₹4,499.18 cr
10.9 cr shares · Micro cap
₹1,303.76 cr
as published
92.4× · 20.13×
EPS ₹4.47 · BV ₹20.51
165.82 / 46.68
₹ cr, as filed
42
9 selected · 21%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -13.9% |
|---|---|
| Against 52-week low | +82.9% |
| Day change | -1.71% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹4.47 |
|---|---|
| Price / earnings | 92.37× |
| Price / book | 20.13× |
| Book value — derived, price ÷ P/B | ₹20.51 |
| Return on equity | 21.79% |
| Operating margin | 47.78% |
| Net margin | 25.27% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 21.79%
- ROE as published
- 21.79%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 43.79 | 11.07 | 1.02 | 47.78% | 25.27% |
| Mar-26 · Q | 44.23 | 10.89 | — | 45.85% | 24.62% |
| FY25-26 | 165.82 | 46.68 | — | 47.01% | 28.15% |
Quarter on quarter
- Revenue, quarter on quarter
- -1.0%
- Net profit, quarter on quarter
- +1.7%
- Operating margin, quarter on quarter
- +193 bps
Disclosure profile 42 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 3 |
| Acquisition | 1 |
| Concall Transcript | 1 |
| Credit Rating | 1 |
| Fundraising | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 9 |
| Procedural | |
| AGM / EGM | 9 |
| SAST | 6 |
| Board Meeting | 3 |
| Newspaper Publication | 3 |
| Allotment | 2 |
| Analyst / Investor Meet | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Charter Amendment | 1 |
| General | 1 |
| Outcome | 1 |
| Postal Ballot | 1 |
| Record Date | 1 |
| Trading Window | 1 |
| Procedural sub-total | 33 |
| Total | 42 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
42 filings · 9 selected · busiest 2026-07-21 and 2026-09-30
Filing rhythm · the twelve most recent
2026-09-162026-10-01
SelectedProcedural
Filings
42 in the window · 26 earlier on record
-
1 October 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Please refer to our Scrutinizer Report and Voting Results of 45th Annual General Meeting counter signed by the Chairman.
AGM/EGM / AGM View filing →
-
1 October 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Please refer to our counter signed Scrutinizer's Report of 45th Annual General Meeting.
AGM/EGM / AGM View filing →
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Kindly refer to the attachment.
AGM/EGM / AGM View filing →
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please refer to our revised outcome of the Annual General Meeting due to typographical error.
AGM/EGM / AGM View filing →
-
30 September 2026 ·
Amendments to Memorandum & Articles of Association
Please refer to the Intimation of amendment to Articles of Association of the Company.
Company Update / Amendments to Memorandum & Articles of Association View filing →
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please refer to the outcome of 45th Annual General Meeting held on 30.09.2026
AGM/EGM / AGM View filing →
-
23 September 2026 ·
Closure of Trading Window
Kindly refer to the intimation of trading window closure.
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Newspaper Publication
Please refer to the Newspaper Publication of Corrigendum to the Notice of 45th Annual General Meeting.
Company Update / Newspaper Publication View filing →
-
21 September 2026 ·
Corrigendum To The Notice Of Annual General Meeting.
Please refer to the attachment.
AGM/EGM / AGM View filing →
-
18 September 2026 ·
Corporate Action-Fixed Record Date For Dividend For FY 2025-26
Kindly refer to the attachment.
Corp. Action / Record Date View filing →
-
18 September 2026 ·
-
16 September 2026 ·
Allotment
Please refer to the Disclosure under Reg 30 of LODR.
Company Update / Allotment of Equity Shares View filing →
-
10 September 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.09.2026
Please refer to the Outcome of the Board meeting held on 10.09.2026
Board Meeting / Outcome of Board Meeting View filing →
-
8 September 2026 ·
Addendum To The Notice Of 45Th Annual General Meeting ('AGM')
Please refer to the attachment
AGM/EGM / AGM View filing →
-
7 September 2026 ·
Board Meeting Intimation for Raising Funds Through Issue Of Non-Convertible Debentures By Way Of Private Placement.
Gujarat Themis Biosyn Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/09/2026 ,inter alia, to consider and approve raising funds through ....
Board Meeting / Board Meeting View filing →
-
7 September 2026 ·
Newspaper Publication
Please refer to newspaper publication of 45th AGM notice .
Company Update / Newspaper Publication View filing →
-
4 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Please refer to attached BRSR for F.Y. 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
4 September 2026 ·
Reg. 34 (1) Annual Report.
Please refer to our Annual Report for F.Y. 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
4 September 2026 ·
Shareholders Meeting - AGM On 30.09.2026
Please refer to the Notice of 45th Annual General Meeting scheduled on 30.09.2026
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pharmaceutical Business Group India Ltd & Others
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
1 September 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On 01-09-2026
Kindly refer to the outcome of the Board Meeting held on 01-09-2026
Board Meeting / Outcome of Board Meeting View filing →
-
28 August 2026 ·
Allotment
Outcome of the Fund Raising Committee held on 28.08.2026 for allotment of equity shares through QIP
Company Update / Allotment of Equity Shares View filing →
-
28 August 2026 ·
Qualified Institutional Placement
Outcome of Fund Raising Committee for QIP Issue Close
Company Update / Qualified Institutional Placement View filing →
-
27 August 2026 ·
Board Meeting Intimation for Intimation Of The Board Meeting
Gujarat Themis Biosyn Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2026 ,inter alia, to consider and approve Please refer to the intimation ....
Board Meeting / Board Meeting View filing →
-
25 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Related To QIP
Please refer to the attachment
Others / Outcome without intimation View filing →
-
25 August 2026 ·
Announcement Under Reg 30 (LODR) - Updates (Audited Financial Statements)
Please refer to our Announcement under Reg 30 (LODR) - Updates (Audited Financial Statements - F.Y. 2025-26)
Company Update / General View filing →
-
14 August 2026 ·
Earnings Call Transcript
Earnings Call Transcript
Company Update / Earnings Call Transcript View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Outcome
Please refer to our submission of Call Recordings of the investor/analyst Conference Call held on Monday, August 10, 2026 (IST).
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Investor Presentation
Please refer to our investors presentation for the quarter ended 30.06.2026
Company Update / Investor Presentation View filing →
-
7 August 2026 ·
Results- Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2026
Please refer to the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June ,2026
Result / Financial Results View filing →
-
7 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026
Please refer to the outcome of the Board meeting held on 07.08.2026
Board Meeting / Outcome of Board Meeting View filing →
-
5 August 2026 ·
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sachin D Patel
Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011 View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Please refer to the concall invite to discuss the 1QFY27 Financial performance.
Company Update / Analyst / Investor Meet View filing →
-
31 July 2026 ·
Notice Of Extra-Ordinary General Meeting On 22.08.2026
Please refer to the attachment.
AGM/EGM / EGM View filing →
-
31 July 2026 ·
Board Meeting Intimation for Approval Of Un-Audited Financial Results And Limited Review Report Of Statutory Auditor For The Quarter Ended 30.06.2026
Gujarat Themis Biosyn Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
Board Meeting / Board Meeting View filing →
-
24 July 2026 ·
Newspaper Publication
Please refer to our copies of Newspaper Publication dated 24.07.2026 for Postal Ballot.
Company Update / Newspaper Publication View filing →
-
23 July 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Please refer to the Notice of Postal Ballot 22.07.2026
AGM/EGM / Postal Ballot View filing →
-
21 July 2026 ·
Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 ....
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
21 July 2026 ·
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 21, 2026 for Pharmaceutical ....
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
21 July 2026 ·
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 20, 2026 for Themis Medicare Ltd
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
21 July 2026 ·
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 20, 2026 for Pharmaceutical ....
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
20 July 2026 ·
RSS feed for Gujarat Themis Biosyn Ltd · the 50 most recent filings